Carla Cano

Carla Cano has extensive experience in the field of research and development, particularly in the areas of immunology and oncology. Carla started their career as an undergraduate intern at the Institute of Child Health, where they conducted molecular biology screening for genetic polymorphisms related to atopic diseases. Carla then pursued a Ph.D. at the Centre d’Immunologie de Marseille-Luminy, where they focused on the role of novel players in antibody quality control during B cell differentiation. During their Ph.D., they collaborated with a team of pediatric hematologists and geneticists on rare genetic disease-associated pediatric immune deficiencies.

After completing their Ph.D., Carla worked as a post-doctoral scientist at INSERM U624, where they continued their research on immunology and cell stress, specifically focusing on the discovery of new players in pancreatic cancer promotion and identifying the anti-cancer pathway of cancer cell cannibalism.

Carla then joined CRCM, INSERM U1068 Pôle Luminy, as a scientist. In this role, they designed and executed research projects that contributed to the discovery of new targets for pancreatic cancer therapy. Their work involved target validation and conducting experiments to further therapeutic development.

Following this, Carla joined the Centre d'Information et de Soins de l'Immunodéficience Humaine (CISIH) as a Clinical Research Associate. Carla managed clinical trials and observational cohorts related to HIV, HCV, and HBC. Additionally, they provided molecular and experimental immunology expertise, which facilitated the implementation of retrospective clinical data analyses.

Currently, Carla is working at Imcheck Therapeutics. Carla initially joined as an R&D Senior Scientist, where they served as the project champion and biology leader for early pipeline projects. Their responsibilities included designing and implementing assays for target validation and the discovery of new target functions. Carla was also involved in selecting antibody drug candidates. Carla then progressed to become the Lead Discovery Director, responsible for leading and supervising the research team in the discovery, selection, and optimization of lead drug candidates. Carla ensures project timelines are met and prioritizes discovery programs.

Throughout their career, Carla Cano has demonstrated expertise in research, project management, and leadership in the development of novel therapies in the fields of immunology, oncology, and infectious diseases.

Carla Cano obtained their Ph.D. in Immunology from Université d'Aix-Marseille II from 1999 to 2003. In 2012 to 2013, they attended ISPED School of Public Health at the University of Bordeaux in France and earned a University Diploma in Clinical Research. Additionally, Carla obtained certifications such as the PTI: The Online Pharma & Biopharm Mini-MBA and EBD Academy: Fundamentals of IP for Partnering Deals from Informa in November 2020 and April 2020 respectively.